[1]章斌.188Re直接标记octreotide的方法学[J].国际放射医学核医学杂志,2002,26(5):220-222.
　ZHANG Bin.Investigations of directly labelling octreotide with 188Re[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(5):220-222.
点击复制

188Re直接标记octreotide的方法学(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
26
期数:
2002年第5期
页码:
220-222
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Investigations of directly labelling octreotide with 188Re
作者:
章斌
215006 苏州, 苏州大学附属第一医院核医学科
Author(s):
ZHANG Bin
Department of Nuclear Medicine, First Affiliated Hospital of Soochow University, Suzhou Jiangsu 215006, China
关键词:
奥曲肽; 受体; 生长抑素; 188Re; 同位素标记
Keywords:
octreotide; receptor; somatostatin; 188Re; isotope labelling
分类号:
R817.4
摘要:
188Re标记octreotide可用直接标记法或间接标记法。直接标记法包括预锡化法和分步还原法,分步还原法需先用还原剂还原octreotide,然后用SnCl2还原188ReO4-进行直接标记;预锡化法则直接以SnCl2还原octreotide和188ReO4-,打开octreotide分子内双硫键,使188Re直接标记octreotide。预锡化直接标记法简便快速,能够得到较高的放化纯度,无须进一步纯化,适合用于制备药盒。
Abstract:
Octreotide can be labelled with 188Re by using the direct labelling approach and the bifunctional chelate approach.The direct labelling approach concludes pretinning procedure and two-step reduction method.By pretinning pro-cedure,both octreotide and perrhenate are reduced by SnCl2.Rhenium of a lower oxidation state is bound to octreotide directly.By two-step reduction method,octreotide and the perrhenate are reduced by different reduction agent respectively.The direct radiolabelling approaches allow very high radiochemical purity,high specific activity formulation,low radiocolloid formation and good in vitro stability,without the need for post-radiolabel ling purification to eliminate the un-bound free radioisotope.A kit could be developed which would merely require the mixing of perrhenate with the other reagents in a single vial.

参考文献/References:

[1] Dadachova E, Mirzadeh S. The role of tin in the direct labelling of proteins with rhenium-188[J]. Nucl Med Biol,1997, 24:605-608.
[2] Melendez-Alafort L, Ferro-Flores G, Arteaga-Murphy C, et al. Labelling peptides with rhenium-188[J]. Inter J Pharm,1999, 152:165-172.
[3] Thakur ML, Esbach J, Wilder S, et al. Technetium-99m-labelled somatostatin:preparation and preliminary evaluation[J]. J Labelled Comp Radiopharm, 1993, 32:365-367.
[4] Hosono M, Hosono MN, Haberberger T, et al. Localization of small-cell lung cancer xenografts with Iodine-125-, Indium-111-, and Rhenium-188-somatostatin analogs[J]. Jpn J Cancer Res, 1996, 87:995-1000.
[5] Winnard P Jr, Virzi F, Fogarasi M, et al. Investigations of directly labelling antibodies with rhenium-188[J]. Q J Nucl Med, 1996, 40:151-160.
[6] Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labelled somatostatin receptor-binding peptides[J]. J Nucl Med, 1996, 37:1016-1022.
[7] Iznaga-Escobar N. Direct radiolabeling of monoclonal antibodies with rhenium-188 for radioimmunotherapy of solid tumors-a review of radiolabelling characteristics, quality control and in vitro stability studies[J]. Appl Radiat and Isotope, 2001, 54:399-406.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
　Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
　Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
　Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
　Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
　ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
　YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
　BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[11]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
　LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[12]王佳琼,王自正,姚薇萱,等.乳腺肿瘤生长抑素受体表达与生长抑素受体显像[J].国际放射医学核医学杂志,2006,30(1):17.
　WANG Jia-qiong,WANG Zi-zheng,YAO Wei-xuan,et al.Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):17.

备注/Memo

备注/Memo:
收稿日期:2002-06-10。
作者简介:章斌(1972-),男,江苏苏州人,硕士,主要从事肿瘤核医学研究。
更新日期/Last Update: 1900-01-01